Recruitment of a panel of main KOL surgeons who imagine Nociscan can enhance the prognosis and remedy of discogenic low again ache is a essential step to establishing Nociscan as commonplace of care.
Aclarion’s KOL panel represents spine surgeons at a few of the largest and most influential tutorial facilities and personal practices within the nation, together with leaders of nationwide societies that advocate for protocols to enhance medical therapies.
The Firm intends to activate MRIs for every KOL surgeon to develop Nociscan entry for his or her sufferers and exhibit medical end result enhancements to payers.
Aclarion will launch preliminary scan quantity information earlier than finish of 12 months and start reporting on quarterly scan quantity in 2024 as rising scan quantity is a proxy for rising income and likelihood for an area payer protection choice.
BROOMFIELD, CO, Nov. 08, 2023 (GLOBE NEWSWIRE) — by way of NewMediaWire – Aclarion, Inc., (“Aclarion” or the “Firm”) (Nasdaq: ACON, ACONW), a healthcare know-how firm that’s leveraging biomarkers and proprietary augmented intelligence algorithms to assist physicians determine the placement of continual low again ache, introduced at present that they’ve efficiently achieved their objective of enrolling ten main spine surgical procedure KOLs to help the corporate in driving Nociscan to plain of look after figuring out discogenic low again ache.
“Since executing our IPO final 12 months, Aclarion has constantly achieved catalysts of worth creation that fall into a really concise framework of know-how readiness, medical proof, and surgeon advocacy which are confirmed to deliver disruptive technological developments to plain of care within the healthcare sector,” mentioned Brent Ness, Chief Govt Officer of Aclarion. “The steps we’ve got taken in a brief timeframe exhibit that our actions observe our acknowledged intentions. We’re extremely happy with the KOL panel that has rallied to assist deliver Nociscan to plain of care.”
A cornerstone to the corporate’s technique is vital opinion chief (KOL) advocacy. Aclarion has now achieved its goal of partaking 10 main spine physicians who’re adopting Nociscan of their practices to deal with a serious hole with standard lumbar MR imaging, which can’t differentiate between ache and getting old. Our KOL advisors are centered on advancing value-based healthcare via improved outcomes whereas advocating to societies and payers utilizing affected person information, in addition to peer-reviewed, printed medical proof. “Our KOLs curiosity in Nociscan straight displays the problem of diagnosing and treating low again ache, and we’re happy to have these physicians advancing spine care with Nociscan,” acknowledged Ryan Bond, Chief Technique Officer of Aclarion.
KOLs, consultants, and advisors now embody:
- Chris Ames, MD; College of CA San Francisco
- Gregory Basil, MD MBA; College of Miami
- Sigurd Berven, MD; College of CA San Francisco
- George Frey, MD; Introduction Health Colorado
- Roger Hartl, MD; Weill Cornell Mind and Backbone Middle, New York, NY
- Dean Karahalios, MD; Advocate Aroura Health System
- James Keller, MD; College of Michigan Health West
- Alpesh Patel, MD MBA; Northwestern
- Eric Potts, MD; St. Vincent’s, Ascension
- Juan Uribe, MD; Barrow Neurological Institute
- Bob Eastlack, MD; Scripps (Surgeon Advisor)
- Timothy Ryken, MD; (Guide)
- Lawrence Tannenbaum, MD; RadNet (MD Advisor)
- Jeffrey Lotz, PhD; College of CA San Francisco (Scientific Advisor)
The Firm will announce MRI entry enlargement for every KOL as their MRIs are onboarded. Drs Frey and Hartl have already got entry and have utilized Nociscan of their medical practices. As MRI entry will increase, so too will potential scan quantity, peer reviewed proof, and income.
For extra details about the BEST Trial, please go to: www.besttrial.org
For details about BACPAC, please go to: https://heal.nih.gov/analysis/clinical-research/back-pain
For extra details about REACH, please go to: www.bacpac-reach.org
For extra details about our printed proof, please go to: www.aclarion.com
For details about entry to Nociscan please go to: www.aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare know-how firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing strategies, biomarkers, and augmented intelligence algorithms to optimize medical therapies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) information from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing strategies extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker information is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan offers essential insights into the placement of a affected person’s low again ache, giving physicians readability to optimize remedy methods. For extra info, please go to www.aclarion.com.
Ahead Wanting Statements
This press launch accommodates forward-looking statements inside the that means of the Personal Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Alternate Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic info, similar to “anticipates,” “believes” and “expects” or comparable expressions, are forward-looking statements. These forward-looking statements are based mostly on the present plans and expectations of administration and are topic to quite a lot of uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra totally in our filings with the Securities and Alternate Fee. Readers are inspired to evaluation the part titled “Danger Elements” within the Firm’s Prospectus dated April 21, 2022, as filed with the Securities and Alternate Fee on April 25, 2022 underneath Rule 424(b)(4), in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Alternate Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new info, future occasions or in any other case.
Kirin M. Smith
PCG Advisory, Inc.